Skin sarcoidosis

Summary

Skin sarcoidosis (MONDO:0006611) is a disease and 6 clinical trials. Top therapeutic interventions include adalimumab, corticotropin, and brepocitinib. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin sarcoidosis
Mondo ID	MONDO:0006611
EFO	EFO:1000767
DOID	DOID:13402
ICD-10-CM	D86.3
NCIT	C34996
SNOMED CT	55941000
UMLS	C0036203
MedGen	19872
GARD	0024444
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	no

Also known as: cutaneous sarcoidosis · sarcoidosis of zone of skin · zone of skin sarcoidosis

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › skin sarcoidosis

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00794274	PHASE2/PHASE3	COMPLETED	The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
NCT02348905	PHASE2/PHASE3	UNKNOWN	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial
NCT05458492	PHASE2	NOT_YET_RECRUITING	Sirolimus in Cutaneous Sarcoidosis
NCT06978725	PHASE2	RECRUITING	A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
NCT00731757	PHASE2	WITHDRAWN	Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis
NCT03910543	PHASE1	COMPLETED	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ADALIMUMAB	4	1
CORTICOTROPIN	4	1
BREPOCITINIB	3	1
CHEMBL4747591	0	1